Production (Stage)
Applied Therapeutics, Inc.
APLT
$0.4099
-$0.0001-0.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 155.77% | -95.44% | -101.98% | -103.12% | -104.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 155.77% | -95.44% | -101.98% | -103.12% | -104.47% |
| Cost of Revenue | -11.60% | -9.58% | -44.45% | -42.11% | -29.87% |
| Gross Profit | 12.96% | -9.96% | 37.11% | 33.18% | 16.82% |
| SG&A Expenses | 168.10% | 171.58% | 76.80% | 22.50% | -2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.71% | 40.55% | 25.85% | 0.88% | -8.69% |
| Operating Income | -45.42% | -61.61% | -47.65% | -17.59% | -5.75% |
| Income Before Tax | 77.52% | 11.81% | -94.08% | -119.93% | -178.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.52% | 11.81% | -94.08% | -119.93% | -178.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.52% | 11.81% | -94.08% | -119.93% | -178.41% |
| EBIT | -45.42% | -61.61% | -47.65% | -17.59% | -5.75% |
| EBITDA | -45.42% | -61.61% | -47.66% | -17.59% | -5.75% |
| EPS Basic | 83.74% | 39.79% | -11.87% | -17.49% | -1.33% |
| Normalized Basic EPS | 83.75% | 39.79% | -11.77% | -17.42% | -1.49% |
| EPS Diluted | 75.47% | 28.55% | -23.33% | -29.59% | -1.32% |
| Normalized Diluted EPS | 83.69% | 39.71% | -11.85% | -17.51% | -1.49% |
| Average Basic Shares Outstanding | 42.40% | 65.79% | 89.89% | 101.61% | 123.81% |
| Average Diluted Shares Outstanding | 44.49% | 68.31% | 92.96% | 105.24% | 123.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |